GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety concerns led to an ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

Higher Post-operative Day 1 (POD1) pain scores were independently associated with increased 30-day infectious and ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

Patients with severely disturbed sleep had the highest comorbidity burden, lowest ejection fraction, and poorest cognitive ...

In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ...

A subset of patients undergoing cervical medial branch blocks experienced meaningful short- to medium-term pain and ...

The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse ...